Larimar Therapeutics, Inc. (LRMR): Capital Expenditures
$91.0K
Year ended 2025-12-31
$153.0K
Trailing 12 months to 2026-06-30
-3.1%
3-year compound annual growth
+8.0%
5-year compound annual growth
-17.1%
10-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $91.0K | -82.3% | 2026-03-19, From 2025-01-01 |
| 2024-12-31 | $515.0K | +214.0% | 2026-03-19, From 2024-01-01 |
| 2023-12-31 | $164.0K | +64.0% | 2025-03-24, From 2023-01-01 |
| 2022-12-31 | $100.0K | -70.0% | 2024-03-14, From 2022-01-01 |
| 2021-12-31 | $333.0K | +437.1% | 2023-03-14, From 2021-01-01 |
| 2020-12-31 | $62.0K | -25.3% | 2022-03-25, From 2020-01-01 |
| 2019-12-31 | $83.0K | -23.1% | 2021-03-04, From 2019-01-01 |
| 2018-12-31 | $108.0K | +96.4% | 2020-03-05, From 2018-01-01 |
| 2017-12-31 | $55.0K | -91.7% | 2020-03-05, From 2017-01-01 |
| 2016-12-31 | $660.0K | +10.9% | 2019-03-14, From 2016-01-01 |
| 2015-12-31 | $595.0K | +925.9% | 2018-03-09, From 2015-01-01 |
| 2014-12-31 | $58.0K | +241.2% | 2017-03-10, From 2014-01-01 |
| 2013-12-31 | $17.0K | +750.0% | 2016-03-15, From 2013-01-01 |
| 2012-12-31 | $2.0K | n/a | 2015-03-25, From 2012-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Larimar Therapeutics, Inc. (LRMR) | 2025-12-31 | $91.0K | -82.3% |
| XBiotech Inc. (XBIT) | 2025-12-31 | $289.0K | -77.8% |
| Prelude Therapeutics Inc (PRLD) | 2025-12-31 | $67.0K | -91.2% |
| Whitehawk Therapeutics, Inc. (WHWK) | 2025-12-31 | $552.0K | -66.6% |
| Ovid Therapeutics Inc. (OVID) | 2025-12-31 | $0 | -100.0% |
| CytomX Therapeutics, Inc. (CTMX) | 2025-12-31 | $220.0K | -29.0% |
| Veradermics, Inc (MANE) | 2025-12-31 | $24.0K | n/a |
| Elite Pharmaceuticals Inc (ELTP) | 2026-03-31 | $925.6K | -43.0% |
| Seres Therapeutics, Inc. (MCRB) | 2025-12-31 | $252.0K | -33.7% |
Compare LRMR, XBIT, PRLD, WHWK side by side · Screen every company in Pharmaceutical Preparations ↗